Wyeth, Diosynth Biotechnology, INC Research and Aptuit - People on the move
people on the move this month.
Pharma giant and outsourcing proponent Wyeth this week promoted Bernard Poussot to the position of chief operating officer (COO) of the firm.
Since April 2006 Mr Poussot has already held the positions of president and vice chairman, which he will continue to fulfil. He will also continue to report to Wyeth's chairman and chief executive officer (CEO) Robert Essner.
Diosynth Biotechnology - the biopharmaceutical contract manufacturing services unit of Dutch firm Organon - has recently appointed Jacques van Kimmenaede as president.
He joins North Carolina-based Diosynth from Organon where he held senior executive management positions in manufacturing and global marketing.
Meanwhile, drug development services firm Aptuit has announced the appointment of Peter Adamski as Chief Financial Officer (CFO).
Mr Adamski brings over 25 years of financial management experience in publicly traded and private equity backed companies, primarily in the health care and pharmaceutical industries, and most recently served as the CFO of Barriersafe Solutions International, said Aptuit.
"We welcome Pete as we transition into a new phase of investment, consolidation and recruitment to expand our global operations," said Michael Griffith, Aptuit's CEO.
He replaces Jon Tropsa, who will return to his private consulting practice but will still continue consulting with Aptuit on a range of issues, said the firm.
Finally, contract research organization (CRO) INC Research, has named Hans Moebius as senior vice president of its central nervous system (CNS) business for Europe.
In this position, Dr Moebius will be responsible for the operations, strategic planning and corporate development of INC's European CNS business and will have management oversight for all CNS and Pediatrics research staff and clinical trials taking place in Europe, said the firm.
Dr. Moebius will also oversee INC Research's expansion into Switzerland and will serve as head of the INC Research Zurich office, which opens in January 2007.
"As we look to further solidify and expand our presence within the European CRO market, Dr Moebius' substantial clinical and management expertise will be extremely beneficial," said Kelvin Logan, president of INC Research, Europe.
Before joining INC Research, Dr. Moebius served for 10 years with Merz Pharmaceuticals, the last five of which he filled the role of chief scientific officer and managing director.
